News · 26 weeks86+188%
2026-03-012026-08-23
Mix4390d
- Insider26(60%)
- Other7(16%)
- SEC Filings6(14%)
- Earnings2(5%)
- Analyst1(2%)
- Offering1(2%)
Latest news
25 items- PRBausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial ResultsDual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. "Helping people see better to live better s
- INSIDERDirector Trebbi Barbara was granted 11,776 shares (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSEC Form 3 filed by new insider Trebbi Barbara3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Paul Laurence E was granted 11,776 shares (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSEC Form 3 filed by new insider Paul Laurence E3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Chersi Robert J was granted 11,776 shares (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chersi Robert J3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERNew insider Appio Thomas claimed ownership of 27,583 shares (SEC Form 3)3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick sold $887,662 worth of shares (52,900 units at $16.78), decreasing direct ownership by 54% to 45,831 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- SECAmendment: SEC Form 8-K/A filed by Bausch + Lomb Corporation8-K/A - Bausch & Lomb Corp (0001860742) (Filer)
- INSIDERDirector Von Eschenbach Andrew C. sold $306,708 worth of shares (18,559 units at $16.53), decreasing direct ownership by 23% to 63,733 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- SECSEC Form 144 filed by Bausch + Lomb Corporation144 - Bausch & Lomb Corp (0001860742) (Subject)
- INSIDERPresident, GPIC Stewart Andrew J. was granted 16,778 shares, increasing direct ownership by 19% to 103,211 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick was granted 9,091 shares, increasing direct ownership by 10% to 98,731 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP of R&D and CMO Hashad Yehia was granted 20,973 shares, increasing direct ownership by 13% to 187,350 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP and CFO Eldessouky Sam was granted 50,335 shares, increasing direct ownership by 15% to 393,527 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERPresident, Surgical Bonnefoy Luc was granted 16,778 shares, increasing direct ownership by 19% to 103,801 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP & Chief Legal Officer Bailey A Robert D was granted 33,557 shares, increasing direct ownership by 15% to 264,241 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERChairman of the Board and CEO Saunders Brent L was granted 281,879 shares and covered exercise/tax liability with 4,231 shares, increasing direct ownership by 28% to 1,256,037 units (SEC Form 4) to satisfy withholding tax4 - Bausch & Lomb Corp (0001860742) (Issuer)
- SECSEC Form 144 filed by Bausch + Lomb Corporation144 - Bausch & Lomb Corp (0001860742) (Subject)
- SECBausch + Lomb Corporation filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Other Events8-K - Bausch & Lomb Corp (0001860742) (Filer)
- PRBausch Health CEO Thomas J. Appio Joins Bausch + Lomb BoardLAVAL, QC, Aug. 6, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026."Bausch + Lomb is an important asset of Bausch Health, and I look forward to working with the board to support its strategy and help drive long-term value for shareholders," said Thomas J. Appio.In addition, Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi have joined the Bausch + Lomb board of directors. The new directors replace Steven Collis, Kare
- PRBausch + Lomb Announces Board of Directors Update, Reaffirms GuidanceBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. ("Bausch Health"), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the company’s outstanding common shares, the Bausch + Lomb Board has appointed four new directors, effective Aug. 5, 2026: Thomas J. Appio, CEO, Bausch Health Robert Chersi, founder of Chersi Services LLC, executive director and a pr
- SECSEC Form 10-Q filed by Bausch + Lomb Corporation10-Q - Bausch & Lomb Corp (0001860742) (Filer)
- SECBausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bausch & Lomb Corp (0001860742) (Filer)
BLCO FAQ
7 questionsWhat does Bausch + Lomb Corporation do?
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic...Where does BLCO stock trade?
Bausch + Lomb Corporation (BLCO) is listed on NYSE.What sector and industry is BLCO in?
Bausch + Lomb Corporation operates in the Health Care sector, Ophthalmic Goods industry.When did Bausch + Lomb Corporation go public?
Bausch + Lomb Corporation (BLCO) completed its IPO in 2022.What are analysts saying about BLCO?
Bausch + Lomb Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $2100.00 price target on 2026-07-28. Recent price targets range from $1500.00 to $2200.00.What companies are similar to BLCO?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), WRBY (Warby Parker Inc.), EYE (National Vision Holdings Inc.), STAA (STAAR Surgical Company). Compare BLCO side-by-side with any of them on Quantisnow.How can I track BLCO on Quantisnow?
Quantisnow aggregates Bausch + Lomb Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLCO to receive live email and push alerts on every new disclosure.